([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate derivatives as pH inhibitor compounds, compositions and methods of use

Abstract

The present invention provides, in part, novel small-molecule inhibitors of PHD, having a structure according to Formula (I), and subformulas thereof: (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein may be useful for the treatment or prevention of diseases, including cardiac diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), pulmonary diseases (e.g., pulmonary inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory diseases (e.g., respiratory infection, acute respiratory distress syndrome), hepatic diseases (e.g., acute liver failure and hepatic fibrosis and cirrhosis), and renal diseases (e.g., acute kidney injury and chronic kidney disease), inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g.stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).